E.V. Reznik1,2,3, A.S. Grigorievskaya1,2, N.V. Vistovskaya2, M.D. Iarovoi1, I.V. Semenyakin2, T.R. Kameneva4,5
1Pirogov Russian National Research Medical University, Moscow
2Medsi Group JSC, Moscow
3Academician G.M. Savel’eva City Clinical Hospital No. 31, Moscow
4Research Institute of Public Health Organization and Medical Management, Moscow
5Federal Scientific and Clinical Center for Resuscitation and Rehabilitation, Solnechnogorsk, Lytkino village
Vaccination is of great importance both to reduce COVID-19 morbidity and to ensure a milder disease in case of infection. Also, the vaccination impacts on the course of post-COVID-19 syndrome. In particular, it decreases the condition probability by 29% in vaccinated patients as compared with the control group. In total, more than 150 vaccines have been developed since the beginning of the COVID-19 pandemic. Most of them were sieved away at various stages of clinical trials. The paper reviews the vaccination efficiency as a general matter and in specific comorbid populations. The authors compared 8 of the most common COVID-19 vaccines: novel coronavirus infection (COVID-19) prevention vaccineы according to several criteria (type, efficiency, and potential side effects of the vaccine). The COVID-19 prevention vaccine (Russia) proved to be the most efficient (97.6%). It had no adverse reactions other than local injection site reactions and a flu-like syndrome. Injection site inflammation, fever, muscle pain, headache, and fatigue are the most common complications after the vaccination. More rarely, post-vaccination myocarditis and vaccination-induced Guillain-Barré syndrome (especially after administration of DNA or RNA-containing vaccines) is reported.
Keywords: vaccination, coronavirus infection, COVID-19, long COVID, vaccine prevention, efficiency, novel coronavirus infection (COVID-19) prevention vaccine.
For citation: Reznik E.V., Grigorievskaya A.S., Vistovskaya N.V., Iarovoi M.D., Semenyakin I.V., Kameneva T.R. Efficiency and safety of COVID-19 vaccines: a comparative analysis. RMJ. 2025;3:16–19. DOI: 10.32364/2225-2282-2025-3-3
